JP2022547885A5 - - Google Patents

Info

Publication number
JP2022547885A5
JP2022547885A5 JP2022514645A JP2022514645A JP2022547885A5 JP 2022547885 A5 JP2022547885 A5 JP 2022547885A5 JP 2022514645 A JP2022514645 A JP 2022514645A JP 2022514645 A JP2022514645 A JP 2022514645A JP 2022547885 A5 JP2022547885 A5 JP 2022547885A5
Authority
JP
Japan
Prior art keywords
nutrin
cdk4
adenovirus
inhibitor
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022514645A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022547885A (ja
JP7834342B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/074980 external-priority patent/WO2021044061A1/en
Publication of JP2022547885A publication Critical patent/JP2022547885A/ja
Publication of JP2022547885A5 publication Critical patent/JP2022547885A5/ja
Application granted granted Critical
Publication of JP7834342B2 publication Critical patent/JP7834342B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022514645A 2019-09-05 2020-09-07 腫瘍溶解性アデノウイルスと、cdk4/6阻害剤と、更なる治療的に活性な薬剤との組み合わせによる腫瘍の処置 Active JP7834342B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19000396.2 2019-09-05
EP19000396 2019-09-05
EP19000406.9 2019-09-12
EP19000406 2019-09-12
PCT/EP2020/074980 WO2021044061A1 (en) 2019-09-05 2020-09-07 Treatment of tumors by a combination of an oncolytic adenovirus, a cdk4/6 inhibitor and a further therapeutically active agent

Publications (3)

Publication Number Publication Date
JP2022547885A JP2022547885A (ja) 2022-11-16
JP2022547885A5 true JP2022547885A5 (cg-RX-API-DMAC7.html) 2023-09-15
JP7834342B2 JP7834342B2 (ja) 2026-03-24

Family

ID=72428285

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022514645A Active JP7834342B2 (ja) 2019-09-05 2020-09-07 腫瘍溶解性アデノウイルスと、cdk4/6阻害剤と、更なる治療的に活性な薬剤との組み合わせによる腫瘍の処置

Country Status (8)

Country Link
US (1) US20220354911A1 (cg-RX-API-DMAC7.html)
EP (1) EP4025229A1 (cg-RX-API-DMAC7.html)
JP (1) JP7834342B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220079551A (cg-RX-API-DMAC7.html)
CN (1) CN114615996A (cg-RX-API-DMAC7.html)
AU (1) AU2020342594A1 (cg-RX-API-DMAC7.html)
CA (1) CA3152965A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021044061A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4578943A4 (en) * 2022-08-25 2026-02-25 Fujifilm Corp PROCESS FOR TARGETING VIRUS PRODUCTION AND CULTURE COMPOSITION

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
ES2188985T3 (es) 1996-08-30 2003-07-01 Jens Peter Furste Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos.
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
AU2003242585A1 (en) 2002-05-27 2003-12-12 Per Sonne Holm Novel use of adenoviruses and nucleic acids coding therefor
WO2012022496A2 (en) * 2010-08-19 2012-02-23 Per Sonne Holm Method for killing tumor stem cells
SG11201507393TA (en) * 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
RU2670762C2 (ru) * 2013-12-31 2018-10-25 Хуаньчжу Фарма Ко., Лтд. Производные 6-(пиримидиноаминопиридин)бензоимидазола, полезные для лечения рака
JP2017516862A (ja) * 2014-05-30 2017-06-22 ブリティッシュ コロンビア キャンサー エージェンシー ブランチ アンドロゲン受容体調節物質及びその使用方法
ES2899913T3 (es) * 2014-09-24 2022-03-15 Salk Inst For Biological Studi Virus tumorales oncolíticos y métodos de uso
CN107849111B (zh) * 2015-05-04 2022-02-22 Vcn生物科学有限公司 在免疫显性腺病毒抗原表位中具有突变的溶瘤腺病毒及其在癌症治疗中的用途
WO2018195202A1 (en) * 2017-04-21 2018-10-25 Pellficure Pharmaceuticals Inc. Compositions and methods for the treatment of cancer
CA3066778A1 (en) * 2017-06-21 2018-12-27 X4 Pharmaceuticals, Inc. Methods for treating cancer
SG11202007873VA (en) * 2018-03-05 2020-09-29 Klinikum Rechts Der Isar Der Technischen Univ Muenchen Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor

Similar Documents

Publication Publication Date Title
Liu et al. The roles of EZH2 in cancer and its inhibitors
Phan et al. P38 kinase in gastrointestinal cancers
Qin et al. Lenvatinib in hepatocellular carcinoma: resistance mechanisms and strategies for improved efficacy
Zhuang et al. The role of m6A methylation in therapy resistance in cancer
Sofi et al. Cyclin-dependent kinases in breast cancer: expression pattern and therapeutic implications
Tudor et al. COX-2 as a potential biomarker and therapeutic target in melanoma
Vilchez et al. Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment
Zandi et al. Dual-specificity phosphatases: therapeutic targets in cancer therapy resistance
Hong et al. LB100, a small molecule inhibitor of PP2A with potent chemo-and radio-sensitizing potential
Ghorab et al. New quinazoline sulfonamide derivatives as potential anticancer agents: Identifying a promising hit with dual EGFR/VEGFR-2 inhibitory and radiosensitizing activity
Zhang et al. HGF-mediated elevation of ETV1 facilitates hepatocellular carcinoma metastasis through upregulating PTK2 and c-MET
Lv et al. Imperatorin induces autophagy and G0/G1 phase arrest via PTEN-PI3K-AKT-mTOR/p21 signaling pathway in human osteosarcoma cells in vitro and in vivo
Mantwill et al. Inhibition of the multidrug-resistant phenotype by targeting YB-1 with a conditionally oncolytic adenovirus: implications for combinatorial treatment regimen with chemotherapeutic agents
Li et al. Multiple functions of the DEAD-box RNA helicase, DDX5 (p68), make DDX5 a superior oncogenic biomarker and target for targeted cancer therapy
Bryant et al. Targeting hypoxia in the treatment of small cell lung cancer
Shibahara et al. TIP60 is required for tumorigenesis in non‐small cell lung cancer
Miller et al. Cyclin‐dependent kinases as therapeutic targets in melanoma
Zheng et al. Radiation-inducible protein RbAp48 contributes to radiosensitivity of cervical cancer cells
Tong et al. The emerging roles of histone demethylases in cancers
Jiang et al. Clinical applicability of renin-angiotensin system inhibitors in cancer treatment
Yu et al. DDX55 promotes hepatocellular carcinoma progression by interacting with BRD4 and participating in exosome‐mediated cell‐cell communication
Kant et al. Discovery of an orally efficacious MYC inhibitor for liver cancer using a GNMT-based high-throughput screening system and structure–activity relationship analysis
JP2021517119A5 (cg-RX-API-DMAC7.html)
Saatloo et al. Akt1 and Jak1 siRNA based silencing effects on the proliferation and apoptosis in head and neck squamous cell carcinoma
Liu et al. Small-molecule and peptide inhibitors of m6A regulators